Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30817656 | 0.76 | NPC1 (0.44) | ALDH1A1GRM1GRM5NR1H3PPARD | |
| SCHEMBL4097446 | 0.76 | NPC1 (0.44) | ALDH1A1GRM1GRM5NR1H3PPARD | |
| SCHEMBL2029240 | 0.71 | RAB9A (0.56) | ALDH1A1GRM1MAPTHPGDPOLB | |
| SCHEMBL1922080 | 0.70 | SMN1; SMN2 (0.56) | ALDH1A1GRM1KMT2A | |
| SCHEMBL11016027 | 0.70 | ALDH1A1 (0.52) | ALDH1A1MAPTIDH1POLBKMT2A | |
| SCHEMBL11012453 | 0.70 | POLB (0.53) | ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL8815935 | 0.70 | HPGD (0.53) | ALDH1A1IDH1HPGDPOLBKMT2A | |
| SCHEMBL2134732 | 0.69 | ALDH1A1 (0.57) | ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL30632368 | 0.69 | MAPT (0.53) | ALDH1A1GRM1PPARAMAPTPOLB | |
| SCHEMBL13034165 | 0.69 | ALDH1A1 (0.54) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2005095391-A1 | THIAZOLIUMS AS TRANSKETOLASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | TKT, RRM2, TYMS | ALDH1A1 766/4885GRM1 4539/4885GRM5 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.